Evidence map›Paper›PMID 38511196›Full record

ArticleFrontiers in aging neuroscience2024

Anosognosia is associated with increased prevalence and faster development of neuropsychiatric symptoms in mild cognitive impairment.

Sharon Wang, Kayden Mimmack, Federica Cacciamani, Michael Elnemais Fawzy, Catherine Munro, Jennifer Gatchel, Gad A Marshall, Geoffroy Gagliardi, Patrizia Vannini

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Sharon WangDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Kayden MimmackDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Federica CacciamaniDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Michael Elnemais FawzyDepartment of Neurology, Brigham and Women's Hospital, Boston, MA, United States.
Catherine MunroDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Jennifer GatchelHarvard Medical School, Boston, MA, United States.
Gad A MarshallDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Geoffroy GagliardiDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Patrizia VanniniDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Brigham and Women's Hospital · USMassachusetts General Hospital · USHarvard University · USMcLean Hospital · USMolécule aux Nanos-objets : Réactivité, Interactions et Spectroscopies · FR

Funding

Decoding neural systems underlying anosognosia for memory loss in aging and Alzheimer's diseaseR01AG061083 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI VANNINI, PATRIZIA · 2019 to 2023
$4.3M
NIA NIH HHS R01 AG061083
6 · The paper itself

Abstract

Introduction: Both the loss of awareness for cognitive decline (a. k.a anosognosia) and neuropsychiatric symptoms (NPS) are common in patients with Alzheimer's disease (AD) dementia, even in prodromal stages, and may exacerbate functional impairment and negatively impact caregiver burden. Despite the high impact of these symptoms on patients and their caregivers, our knowledge of how they develop across the AD spectrum is limited. Here, we explored the cross-sectional and longitudinal associations between anosognosia and NPS in individuals with mild cognitive impairment (MCI). Methods: We included 237 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with a baseline clinical diagnosis of MCI. Everyday Cognition (ECog) questionnaire scores were used to measure complaints from participants and study-partners at baseline and annually over a mean of 4.29 years [standard deviation (SD) = 2.72]. Anosognosia was defined as the study-partner having an ECog score ≥2.5/4 and the participant having an ECog score < 2.5/4 on their baseline measure and their last observation without more than two consecutive deviating observations during the follow-up period. The 12-item study-partner-rated Neuropsychiatric Inventory determined the presence or absence of specific NPS. Survival analyses were performed to analyze the frequency and temporal onset of NPS over time in individuals with and without anosognosia. Results: Thirty-eight out of 237 participants displayed anosognosia. Groups had similar lengths of follow-up at baseline ( Discussion: Loss of awareness for cognitive decline is associated with greater frequency and earlier onset of NPS over time in participants with MCI. These results support the hypothesis of a potential common underlying neurophysiological process for anosognosia and NPS, a finding that needs to be addressed in future studies.

Indexed as

Alzheimer's diseaseanosognosiaawarenessmild cognitive impairmentneuropsychiatric symptoms

Identifiers

PMID38511196
PMCPMC10950916
OpenAlexW4392514918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.